Drugs / DCC-3084
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06287463 | May 2024 → Feb 2026 | castration-resistant prostate carcinoma, melanoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCC-3084 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06287463 ↗ |
| Route | Oral | “Administered orally” NCT06287463 ↗ |